Filana’s Novel Epilepsy Asset Stalled by FDA Hold, Puts Limited Cash Runway in Sharp Focus

Filana Therapeutics Updates on Clinical Hold and Q2 2026 Financials

Filana Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2026, showing cash and cash equivalents of $82.7 million. The company is actively engaging with the FDA regarding a clinical hold on its proof-of-concept trial for simufilam in Tuberous Sclerosis Complex (TSC)-related epilepsy. R&D expenses decreased by 35% to $3.3 million, while G&A expenses significantly dropped by 85% to $6.1 million, primarily due to a non-recurring securities litigation loss contingency from the prior year. The net loss for the quarter was $8.6 million, or $0.18 per share.

• Filana Therapeutics reported a cash and cash equivalents balance of $82.7 million as of June 30, 2026, down from $95.5 million at the end of 2025. The company anticipates unrestricted cash at year-end 2026 to be between $36 million and $40 million, after accounting for a $31.25 million litigation settlement payment made in July 2026.
• The company continues to address the FDA's requests for information to lift the clinical hold on its proof-of-concept trial for simufilam in TSC-related epilepsy. This ongoing regulatory engagement is a key focus, with the company diligently working to meet the FDA's requirements to advance the program.
• Filana Therapeutics is actively involved with the TSC community, sponsoring and participating in the 2026 TSC World Conference. Additionally, peer-reviewed proceedings of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (Eilat XVIII) were published in Epilepsia, including preclinical data supporting the simufilam program in TSC-related epilepsy.

Addressing the Unmet Needs in TSC-related Epilepsy Treatment

Epilepsy remains the most burdensome neurological manifestation of Tuberous Sclerosis Complex, affecting 80–90% of patients over their lifetime and driving significant morbidity, mortality, and healthcare costs. Despite an expanding therapeutic arsenal—from traditional antiseizure medications to targeted mTOR inhibitors and surgical intervention—a substantial proportion of patients remain refractory to treatment, underscoring persistent gaps in disease management. These challenges span pharmacological limitations, treatment complexity, and the compounding impact of neuropsychiatric comorbidities.

• High rates of drug resistance: Up to 70% of TSC-related epilepsy cases are refractory to standard antiseizure medications, with 63% of patients developing treatment-resistant epilepsy; 60% require ≥2 concomitant antiepileptic drugs, further suggesting inadequate seizure control with monotherapy approaches.

• Incomplete efficacy of mTOR inhibitors: While everolimus represents the first disease-modifying therapy for TSC-related epilepsy (approved 2017) and achieves ≥50% seizure reduction in a majority of patients in long-term trials (78% completion at 48 months), clinically relevant seizure suppression is seen in only up to 40% of patients overall, leaving a large subset with uncontrolled seizures. Late treatment failure has also been documented, with cases of sustained response for a decade followed by lesion regrowth despite proper dosing.

• Drug-drug interaction complexity: Combination regimens introduce pharmacokinetic challenges—for example, cenobamate significantly reduces everolimus serum levels (from 5.1 to 3.4 ng/mL, P=0.01221) via presumed CYP3A4 induction, complicating dosing strategies in patients on concurrent mTOR inhibitor therapy.

• Underlying pathophysiology not fully addressed: Current symptomatic approaches do not directly target the hyperactivated mTOR signaling and disrupted GABAergic interneuron development that underlie TSC-related epileptogenesis, highlighting an unmet need for therapies addressing disease mechanism rather than seizure symptoms alone.

• Surgical candidacy limitations: Although tuberectomy achieves seizure freedom in >60% of eligible patients (with Engel class I outcomes improving from 52% to 63% with better epileptogenic zone localization), not all TSC patients are surgical candidates, and decision-making is often more complex than in other resectable epilepsy syndromes.

• Neuropsychiatric comorbidity burden: Epilepsy frequently coexists with TSC-associated neuropsychiatric disorder (TAND), with autism spectrum disorder in 42% of patients and intellectual disability in 67.6%. Uncontrolled seizures correlate with higher rates of intellectual disability and more pronounced TAND manifestations, indicating that seizure control alone is insufficient for comprehensive patient management.

• Gaps in disease surveillance and care standardization: Routine EEG and MRI monitoring occurs in only 30% of patients, and 12% have no documented antiepileptic drug use, pointing to potential undertreatment and inconsistent surveillance practices across the TSC population.

• Substantial economic burden: Patients with TSC and epilepsy incur threefold higher clinical costs (£14,335 vs. £4,448) compared to the general population, with costs escalating alongside each additional TSC-related manifestation—reflecting the compounding clinical and economic impact of inadequately controlled disease.

Unpacking the Genetic Drivers of TSC-related Epilepsy

Tuberous Sclerosis Complex (TSC)-related epilepsy is fundamentally driven by pathogenic loss-of-function variants in the TSC1 or TSC2 genes. These mutations lead to hyperactivation of the mammalian target of rapamycin (mTOR) signaling pathway, a central integrator of cell growth, proliferation, and metabolic signaling. The resulting mTOR overactivation disrupts the balance of excitatory and inhibitory synaptic transmission, leading to hippocampal hyperexcitability and enhanced neuronal excitability. This dysregulation can directly induce seizures, as demonstrated in mouse models where acute biallelic Tsc1 deletion triggered epilepsy even before the development of significant histological changes. The genetic variant plays a role in the clinical phenotype, with TSC2 mutations being associated with an earlier seizure onset and a greater nodule burden compared to TSC1 mutations. Furthermore, the severity of epilepsy and associated neuropathology correlates in a dose-dependent manner with the level of neuronal mTOR hyperactivity.

The hyperactive mTOR pathway instigates significant downstream cellular and inflammatory consequences that contribute to epileptogenesis. Reactive astrogliosis is a primary pathological feature, with TSC-deficient astrocytes differentiating into a disease-associated reactive state characterized by pronounced morphological changes and the upregulation of neurodegenerative risk-factor proteins. Concurrently, mTOR-mediated inflammatory mechanisms play a critical role. Studies in animal models show increased expression of specific cytokines and chemokines, notably IL-1β (primarily localized to astrocytes) and CXCL10, in the neocortex and hippocampus. Crucially, these inflammatory changes are observed prior to the onset of epilepsy, indicating they are a contributing cause rather than a secondary effect of seizures. Pharmacological intervention with an mTORC1 inhibitor has been shown to reverse this inflammatory marker expression, while inhibitors of IL-1β and CXCL10 can reduce seizure frequency and prolong survival in mouse models.

Further layers of dysregulation occur at the level of gene and microRNA expression, contributing to a cycle of network dysfunction. Epileptogenic tubers exhibit overexpression of a coordinated set of microRNAs (including miRs 23a and 34a) which repress proteins essential for synaptic signal transmission. These microRNAs also directly target the TSC1 gene, creating a feedback loop that further suppresses the TSC1-TSC2 complex and reduces levels of its protein product, hamartin. This molecular pathology underlies the formation of structural brain abnormalities, such as cortical tubers, which result from abnormal corticogenesis during fetal development. These lesions are not static; migrating glial and neuronal precursors from the subventricular zone can form new micronodules and infiltrate forebrain structures, progressively disrupting neural network function and contributing to the refractory nature of epilepsy in many patients.

Simufilam's Crossroads: Navigating a Clinical Hold and Past Setbacks

The recent clinical hold placed on simufilam's proof-of-concept trial for Tuberous Sclerosis Complex (TSC)-related epilepsy casts a long shadow over Filana Therapeutics. This development is particularly poignant given the drug's complex journey. Simufilam, an oral small molecule, operates through a novel mechanism: targeting and reversing an altered conformation of the scaffolding protein filamin A (FLNA). Early Phase 2a studies in Alzheimer's disease (AD) patients showed promising reductions in key AD biomarkers, including tau, neurogranin, and neuroinflammation markers, by disrupting aberrant FLNA interactions with receptors like α7-nicotinic acetylcholine receptor and toll-like receptor 4. This unique approach also demonstrated an ability to normalize overactive mTOR and improve insulin sensitivity in AD patient lymphocytes.

However, the path forward for simufilam in AD proved challenging, with two Phase 3 trials failing to meet their co-primary or secondary endpoints for cognitive and functional improvements. This outcome, despite the earlier biomarker successes, highlights a critical hurdle in drug development: translating mechanistic insights and biomarker changes into tangible clinical benefits. The current clinical hold in TSC-related epilepsy, an indication where preclinical models showed FLNA inhibition could reduce seizures, now adds another layer of regulatory and clinical uncertainty.

For Filana, the implications are substantial:

• Regulatory Scrutiny: The hold signals unresolved questions from the FDA, demanding significant resources and time to address, potentially delaying or halting the TSC program.

• Efficacy Doubts: The repeated challenges in demonstrating clinical efficacy across different indications raise fundamental questions about simufilam's overall therapeutic potential, despite its intriguing mechanism.

• Financial Strain: With a limited cash position and reduced R&D spending, the company faces immense pressure to navigate these setbacks, potentially impacting its ability to explore other promising FLNA-targeting applications, such as in colorectal cancer, where preclinical data also exists for PTI-125.

The future of FLNA targeting as a therapeutic strategy remains compelling, given its broad involvement in various pathologies. However, for simufilam and Filana, this clinical hold represents a critical juncture, demanding a clear path forward to overcome past clinical disappointments and demonstrate definitive patient benefit.